• 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8


RHEACELL is dedicated to the development of pharmaceuticals based on ABCB5-positive (ABCB5+) mesenchymal stem cells as a platform technology. An integral part of RHEACELL's research program is the development of novel and innovative therapeutic approaches and their review in clinical trials. In the end, patients should be offered new treatment options for diseases that have not been or are insufficiently treatable.

As part of the development process of stem cell-based pharmaceuticals RHEACELL makes use of several patents hold by Havard University/Cambridge that are worldwide exclusively licensed to RHEACELL. Markus Frank, M. D., Professor of Pediatrics and Dermatology at Harvard Medical School, is assisting RHEACELL as scientific advisor. He has particular expertise in stem cell research.

Since mid of 2016 RHEACELL is recruiting patients with chronic venous ulcers (CVU) for a phase I/IIa clinical study with autologous (patient-derived) ABCB5+ mesenchymal stem cells.

Since the end of 2017 RHEACELL is also recruiting patients for phase I/IIa clinical studies with allogeneic (donor-derived) ABCB5+ mesenchymal stem cells for the following indications: chronic venous ulcers (CVU), diabetic foot ulcers (DFU) and peripheral arterial occlusive disease (PAOD).

Since the end of 2018 RHEACELL is also recruiting patients with recessive dystrophic epidermolysis bullosa (RDEB) for a phase I/IIa clinical study with allogeneic (donor-derived) ABCB5+ mesenchymal stem cells.

Furthermore, studies are being planned in cooperation with various research centers in the fields of limbal stem cell deficiency, liver and kidney regeneration and tumor diseases.

to the study centers >>

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok